Completed
Thymopentin's Effect on HIV-1 Infectivity and Immune System in HIV Infected Patients
What is being tested
Thymopentin
Drug
Who is being recruted
Blood-Borne Infections+14
+ Urogenital Diseases
+ Genital Diseases
Over 18 Years
+13 Eligibility Criteria
How is the trial designed
Treatment Study
Interventional
Summary
Principal SponsorImmunobiology Research Institute
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
This study focuses on HIV-infected individuals who have not yet developed AIDS. The main goal is to investigate the effects of a drug called Timunox, or thymopentin, on reducing the amount and frequency of HIV detection in blood and semen. The study also aims to understand if thymopentin can boost the immune system and change the clinical findings in these patients, potentially improving their health status and quality of life.
Principal SponsorImmunobiology Research Institute
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAIDS-Related ComplexHIV SeropositivityHIV Infections
Criteria
4 inclusion criteria required to participate
Allowed prior and concurrent medication: Aerosolized pentamidine
Patients with HIV "wasting syndrome" are included
Seropositive for HIV-1 (ELISA assay) confirmed by Western blot. HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of patients' peripheral blood monocytes (PBMC) on two separate occasions
Voluntarily sign consent
9 exclusion criteria prevent from participating
AIDS as defined by the CDC (except for those with HIV "wasting syndrome")
Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry
Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products
Hypersensitivity to thymopentin
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Immunobiology Research Institute
Annandale, United StatesOpen Immunobiology Research Institute in Google MapsCompletedOne Study Center